GlobalData on MSN
Artivion treats first subject in trial of Arcevo LSA stent graft
Participants included in the trial have been diagnosed with either aortic dissection or aneurysm involving the aortic arch.
Ja'Cobey James was found guilty of second-degree murder for shooting Joseph Liebe, a total stranger, on Wallace Lake Road in ...
Artivion, Inc. , a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and ...
Fort Stockton senior manager and trainer Prestyn Armendariz was never able to play football until he walked in pads for the ...
Endovascular Stent Grafts Market to Reach $1.76 billion by 2032, Driven by Aging Populations and Advances in Device Durability Request for customizatio The global Endovascular Stent Grafts ...
Intermountain Health surgeons have achieved a medical milestone for Utah patients by successfully performing the state’s first minimally invasive ascending ...
Artivion reported strong fiscal second-quarter earnings and raised its full-year outlook, citing renewed momentum in mechanical heart valves and continued adoption of its new aortic stent graft.
Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” ...
Intermountain Health surgeons have achieved a medical milestone for Utah patients by successfully performing the state’s first procedure to repair a lesion or t ...
Artivion Inc. (($AORT)) announced an update on their ongoing clinical study. Artivion Inc. has announced a new clinical study titled ‘A ...
StockStory.org on MSN
AORT Q3 Deep Dive: AMDS and On-X Outperform, Pipeline and Reimbursement Bolster Outlook
Medical device company Artivion (NYSE:AORT) reported Q3 CY2025 results , with sales up 18.4% year on year to $113.4 million.
What physicians need to know about the expanded carotid artery stenting coverage, including choice of therapy, shared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results